Prescription Drugs

CLINICAL PHARMACOLOGY Mechanism Of Action Influenza illness and its complications follow infection with influenza viruses. Global surveillance of influenza identifies yearly antigenic variants. Since 1977, antigenic variants of influenza A (H1N1 and H3N2) viruses and influenza B viruses have been in global circulation. Public health authorities give annual influenza vaccine composition recommendations. Inactivated influenza vaccines are standardized to contain the hemagglutinins of influenza viruses representing the virus types or subtypes likely to circulate in the United States during the influenza season. Two influenza type B virus lineages (Victoria and Yamagata) are of public health importance because they have co-circulated since 2001. FLUARIX (trivalent influenza vaccine) contains 2 influenza A subtype viruses and one influenza type B virus. Specific levels of hemagglutination-inhibition (HI) antibody titer post-vaccination with inactivated influenza virus vaccines have not been correlated with protection from influenza illness but the HI antibody titers have been used as a measure of vaccine activity. In some human challenge studies, HI antibody titers of ≥1:40 have been associated with protection from influenza illness in up to 50% of subjects.1,2 Antibody against one influenza virus type or subtype confers little or no protection against another virus. Furthermore, antibody to one antigenic variant of influenza virus might not protect against a new antigenic variant of the same type or subtype. Frequent development of antigenic variants through antigenic drift is the virological basis for seasonal epidemics and the reason for the usual replacement of one or more influenza viruses in each year's influenza vaccine. Annual revaccination is recommended because immunity declines during the year after vaccination, and because circulating strains of influenza virus change from year to year. Clinical Studies Efficacy Against Culture-Confirmed Influenza The efficacy experience with FLUARIX is relevant to FLUARIX QUADRIVALENT because both vaccines are manufactured using the same process and have overlapping compositions [see DESCRIPTION]. The efficacy of FLUARIX was evaluated in a randomized, double-blind, placebo-controlled trial conducted in 2 European countries during the 2006-2007 influenza season. Efficacy of FLUARIX, containing A/New Caledonia/20/1999 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004 influenza virus strains, was defined as the prevention of culture-confirmed influenza A and/or B cases, for vaccine antigenically matched strains, compared with placebo. Healthy subjects aged 18 through 64 years (mean age: 40 years) were randomized (2:1) to receive FLUARIX (n = 5,103) or placebo (n = 2,549) and monitored for influenza-like illnesses (ILI) starting 2 weeks postvaccination and lasting for approximately 7 months. In the overall population, 60% of subjects were female and 99.9% were white. Culture-confirmed influenza was assessed by active and passive surveillance of ILI. Influenza-like illness was defined as at least one general symptom (fever ≥100°F and/or myalgia) and at least one respiratory symptom (cough and/or sore throat). After an episode of ILI, nose and throat swab samples were collected for analysis; attack rates and vaccine efficacy were calculated (Table 6). Table 6: FLUARIX (Trivalent Formulation): Attack Rates and Vaccine Efficacy against Culture- Confirmed Influenza A and/or B in Adults (Total Vaccinated Cohort) N n Attack Rates (n/N) Vaccine Efficacy % % LL UL Antigenically Matched Strainsa FLUARIX 5,103 49 1.0 66.9b 51.9 77.4 Placebo 2,549 74 2.9 — — — All Culture-Confirmed Influenza (Matched, Unmatched, and Untyped)c FLUARIX 5,103 63 1.2 61.6b 46.0 72.8 Placebo 2,549 82 3.2 — — — aThere were no vaccine matched culture-confirmed cases of A/New Caledonia/20/1999 (H1N1) or B/Malaysia/2506/2004 influenza virus strains with FLUARIX or placebo. bVaccine efficacy for FLUARIX exceeded a pre-defined threshold of 35% for the lower limit of the 2-sided 95% CI. cOf the 22 additional cases, 18 were unmatched and 4 were untyped; 15 of the 22 cases were A (H3N2) (11 cases with FLUARIX and 4 cases with placebo). In a post-hoc, exploratory analysis by age, vaccine efficacy (against culture-confirmed influenza A and/or B cases, for vaccine antigenically matched strains) in subjects aged 18 through 49 years was 73.4% (95% CI: 59.3, 82.8) (number of influenza cases: FLUARIX [n = 35/3,602] and placebo [n = 66/1,810]). In subjects aged 50 through 64 years, vaccine efficacy was 13.8% (95% CI: 137.0, 66.3) (number of influenza cases: FLUARIX [n = 14/1,501] and placebo [n = 8/739]). As the trial lacked statistical power to evaluate efficacy within age subgroups, the clinical significance of these results is unknown. Immunological Evaluation Of FLUARIX QUADRIVALENT In Adults Trial 1 was a randomized, double-blind (2 arms) and open-label (one arm), active-controlled, safety, immunogenicity, and non-inferiority trial. In this trial, subjects received FLUARIX QUADRIVALENT (n = 1,809) or one of 2 formulations of comparator trivalent influenza vaccine (FLUARIX, TIV-1, n = 608 or TIV-2, n = 534), each containing an influenza type B virus that corresponded to one of the 2 type B viruses in FLUARIX QUADRIVALENT (a type B virus of the Victoria lineage or a type B virus of the Yamagata lineage). Subjects aged 18 years and older (mean age: 58 years) were evaluated for immune responses to each of the vaccine antigens 21 days following vaccination. In the overall population, 57% of subjects were female; 69% were white, 27% were Asian, and 4% were of other racial/ethnic groups. The immunogenicity endpoints were GMTs of serum hemagglutination-inhibition (HI) antibodies adjusted for baseline, and the percentage of subjects who achieved seroconversion, defined as a prevaccination HI titer of <1:10 with a post-vaccination titer ≥1:40 or at least a 4fold increase in serum HI antibody titer over baseline to ≥1:40 following vaccination, performed on the According-to-Protocol (ATP) cohort for whom immunogenicity assay results were available after vaccination. FLUARIX QUADRIVALENT was noninferior to both TIVs based on adjusted GMTs (upper limit of the 2sided 95% CI for the GMT ratio [TIV/FLUARIX QUADRIVALENT] ≤1.5) and seroconversion rates (upper limit of the 2sided 95% CI on difference of the TIV minus FLUARIX QUADRIVALENT ≤10%). The antibody response to influenza B strains contained in FLUARIX QUADRIVALENT was higher than the antibody response after vaccination with a TIV containing an influenza B strain from a different lineage. There was no evidence that the addition of the second B strain resulted in immune interference to other strains included in the vaccine (Table 7). Table 7: FLUARIX QUADRIVALENT: Immune Responses to Each Antigen 21 Days after Vaccination in Adults (ATP Cohort for Immunogenicity) GMTs FLUARIX QUADRIVALENTa Trivalent Influenza Vaccine (TIV) TIV-1 (B Victoria)b TIV-2 (B Yamagata)c n = 1,809 (95% CI) n = 608 (95% CI) n = 534 (95% CI) A/California/7/2009 (H1N1) 201.1 (188.1, 215.1) 218.4 (194.2, 245.6) 213.0 (187.6, 241.9) A/Victoria/210/2009 (H3N2) 314.7 (296.8, 333.6) 298.2 (268.4, 331.3) 340.4 (304.3, 380.9) B/Brisbane/60/2008 (Victoria lineage) 404.6 (386.6, 423.4) 393.8 (362.7, 427.6) 258.5 (234.6, 284.8) B/Brisbane/3/2007 (Yamagata lineage) 601.8 (573.3, 631.6) 386.6 (351.5, 425.3) 582.5 (534.6, 634.7) Seroconversiond n = 1,801 % (95% CI) n = 605 % (95% CI) n = 530 % (95% CI) A/California/7/2009 (H1N1) 77.5 (75.5, 79.4) 77.2 (73.6, 80.5) 80.2 (76.5, 83.5) A/Victoria/210/2009 (H3N2) 71.5 (69.3, 73.5) 65.8 (61.9, 69.6) 70.0 (65.9, 73.9) B/Brisbane/60/2008 (Victoria lineage) 58.1 (55.8, 60.4) 55.4 (51.3, 59.4) 47.5 (43.2, 51.9) B/Brisbane/3/2007 (Yamagata lineage) 61.7 (59.5, 64.0) 45.6 (41.6, 49.7) 59.1 (54.7, 63.3) ATP = Accordingtoprotocol; GMT = Geometric mean antibody titer; CI = Confidence Interval. ATP cohort for immunogenicity included subjects for whom assay results were available after vaccination for at least one trial vaccine antigen. aContained the same composition as FLUARIX (trivalent formulation) manufactured for the 2010-2011 season and an additional influenza type B virus of Yamagata lineage. bContained the same composition as FLUARIX manufactured for the 2010-2011 season (2 influenza A subtype viruses and an influenza type B virus of Victoria lineage). cContained the same 2 influenza A subtype viruses as FLUARIX manufactured for the 2010-2011 season and an influenza type B virus of Yamagata lineage. dSeroconversion defined as a pre-vaccination HI titer of <1:10 with a post-vaccination titer ≥1:40 or at least a 4-fold increase in serum titers of HI antibodies to ≥1:40. Immunological Evaluation Of FLUARIX QUADRIVALENT In Children Trial 2 was a randomized, double-blind, active-controlled, safety, immunogenicity, and non-inferiority trial. In this trial, subjects received FLUARIX QUADRIVALENT (n = 791) or one of 2 formulations of comparator trivalent influenza vaccine (FLUARIX, TIV-1, n = 819 or TIV-2, n = 801), each containing an influenza type B virus that corresponded to one of the 2 type B viruses in FLUARIX QUADRIVALENT (a type B virus of the Victoria lineage or a type B virus of the Yamagata lineage). In children aged 3 through 17 years, immune responses to each of the vaccine antigens were evaluated in sera 28 days following 1 or 2 doses. In the overall population, 52% of subjects were male; 56% were white, 29% were Asian, 12% were black, and 3% were of other racial/ethnic groups. The immunogenicity endpoints were GMTs adjusted for baseline, and the percentage of subjects who achieved seroconversion, defined as a pre-vaccination HI titer of <1:10 with a post-vaccination titer ≥1:40 or at least a 4fold increase in serum HI titer over baseline to ≥1:40, following vaccination, performed on the ATP cohort for whom immunogenicity assay results were available after vaccination. FLUARIX QUADRIVALENT was non-inferior to both TIVs based on adjusted GMTs (upper limit of the 2sided 95% CI for the GMT ratio [TIV/FLUARIX QUADRIVALENT] ≤1.5) and seroconversion rates (upper limit of the 2sided 95% CI on difference of the TIV minus FLUARIX QUADRIVALENT ≤10%). The antibody response to influenza B strains contained in FLUARIX QUADRIVALENT was higher than the antibody response after vaccination with a TIV containing an influenza B strain from a different lineage. There was no evidence that the addition of the second B strain resulted in immune interference to other strains included in the vaccine (Table 8). Table 8: FLUARIX QUADRIVALENT: Immune Responses to Each Antigen 28 Days after Last Vaccination in Children Aged 3 through 17 Years (ATP Cohort for Immunogenicity) GMTs FLUARIX QUADRIVALENTa Trivalent Influenza Vaccine (TIV) TIV-1 (B Victoria)b TIV-2 (B Yamagata)c n = 791 (95% CI) n = 818 (95% CI) n = 801 (95% CI) A/California/7/2009 (H1N1) 386.2 (357.3, 417.4) 433.2 (401.0, 468.0) 422.3 (390.5, 456.5) A/Victoria/210/2009 (H3N2) 228.8 (215.0, 243.4) 227.3 (213.3, 242.3) 234.0 (219.1, 249.9) B/Brisbane/60/2008 (Victoria lineage) 244.2 (227.5, 262.1) 245.6 (229.2, 263.2) 88.4 (81.5, 95.8) B/Brisbane/3/2007 (Yamagata lineage) 569.6 (533.6, 608.1) 224.7 (207.9, 242.9) 643.3 (603.2, 686.1) Seroconversiond n = 790% (95% CI) n = 818% (95% CI) n = 800% (95% CI) A/California/7/2009 (H1N1) 91.4 (89.2, 93.3) 89.9 (87.6, 91.8) 91.6 (89.5, 93.5) A/Victoria/210/2009 (H3N2) 72.3 (69.0, 75.4) 70.7 (67.4, 73.8) 71.9 (68.6, 75.0) B/Brisbane/60/2008 (Victoria lineage) 70.0 (66.7, 73.2) 68.5 (65.2, 71.6) 29.6 (26.5, 32.9) B/Brisbane/3/2007 (Yamagata lineage) 72.5 (69.3, 75.6) 37.0 (33.7, 40.5) 70.8 (67.5, 73.9) ATP = Accordingtoprotocol; GMT = Geometric mean antibody titer; CI = Confidence Interval. ATP cohort for immunogenicity included subjects for whom assay results were available after vaccination for at least one trial vaccine antigen. aContained the same composition as FLUARIX (trivalent formulation) manufactured for the 2010-2011 season and an additional influenza type B virus of Yamagata lineage. bContained the same composition as FLUARIX manufactured for the 2010-2011 season (2 influenza A subtype viruses and an influenza type B virus of Victoria lineage). cContained the same 2 influenza A subtype viruses as FLUARIX manufactured for the 2010-2011 season and an influenza B virus of Yamagata lineage. dSeroconversion defined as a pre-vaccination HI titer of <1:10 with a post-vaccination titer ≥1:40 or at least a 4-fold increase in serum titers of HI antibodies to ≥1:40. REFERENCES 1. Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res. 2004;103:133-138. 2. Hobson D, Curry RL, Beare AS, et al. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg Camb. 1972;70:767-777.

FLUARIX QUADRIVALENT (influenza vaccine) Suspension for Intramuscular Injection DESCRIPTION FLUARIX QUADRIVALENT, Influenza Vaccine, for intramuscular injection, is a sterile, colorless, and slightly opalescent suspension. FLUARIX QUADRIVALENT is prepared from influenza viruses propagated in embryonated chicken eggs. Each of the influenza viruses is produced and purified separately. After harvesting the virus-containing fluids, each influenza virus is concentrated and purified by zonal centrifugation using a linear sucrose density gradient solution containing detergent to disrupt the viruses. Following dilution, the vaccine is further purified by diafiltration. Each influenza virus solution is inactivated by the consecutive effects of sodium deoxycholate and formaldehyde leading to the production of a “split virus.” Each split inactivated virus is then suspended in sodium phosphate-buffered isotonic sodium chloride solution. Each vaccine is formulated from the split inactivated virus solutions. FLUARIX QUADRIVALENT has been standardized according to US Public Health Service (USPHS) requirements for the 20172018 influenza season and is formulated to contain 60 micrograms (mcg) hemagglutinin (HA) per 0.5mL dose, in the recommended ratio of 15 mcg HA of each of the following 4 influenza virus strains: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 (H1N1) pdm09-like virus), A/Hong Kong/4801/2014 (H3N2) NYMC X-263B, B/Brisbane/60/2008, and B/Phuket/3073/2013. FLUARIX QUADRIVALENT is formulated without preservatives. FLUARIX QUADRIVALENT does not contain thimerosal. Each 0.5mL dose also contains octoxynol-10 (TRITON®X-100) ≤0.115 mg, α-tocopheryl hydrogen succinate ≤0.135 mg, and polysorbate 80 (Tween 80) ≤0.550 mg. Each dose may also contain residual amounts of hydrocortisone ≤0.0016 mcg, gentamicin sulfate ≤0.15 mcg, ovalbumin ≤0.050 mcg, formaldehyde ≤5 mcg, and sodium deoxycholate ≤65 mcg from the manufacturing process. The tip caps and plungers of the prefilled syringes of FLUARIX QUADRIVALENT are not made with natural rubber latex.

INDICATIONS FLUARIX® QUADRIVALENT is indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine [see DESCRIPTION]. FLUARIX QUADRIVALENT is approved for use in persons aged 3 years and older. DOSAGE AND ADMINISTRATION For intramuscular injection only. Dosage And Schedule The dose and schedule for FLUARIX QUADRIVALENT are presented in Table 1. Table 1: FLUARIX QUADRIVALENT: Dosing Age Vaccination Status Dose and Schedule 3 through 8 years Not previously vaccinated with influenza vaccine Two doses (0.5-mL each) at least 4 weeks apart Vaccinated with influenza vaccine in a previous season One or 2 dosesa (0.5-mL each) 9 years and older Not applicable One 0.5-mL dose aOne dose or 2 doses (0.5mL each) depending on vaccination history as per the annual Advisory Committee on Immunization Practices (ACIP) recommendation on prevention and control of influenza with vaccines. If 2 doses, administer each 0.5mL dose at least 4 weeks apart. Administration Instructions Shake well before administration. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If either of these conditions exists, the vaccine should not be administered. Attach a sterile needle to the prefilled syringe and administer intramuscularly. The preferred site for intramuscular injection is the deltoid muscle of the upper arm. Do not inject in the gluteal area or areas where there may be a major nerve trunk. Do not administer this product intravenously, intradermally, or subcutaneously. HOW SUPPLIED Dosage Forms And Strengths FLUARIX QUADRIVALENT is a suspension for injection. Each 0.5mL dose is supplied in singledose prefilled TIPLOK® syringes. Storage And Handling NDC 58160-907-41 Syringe in Package of 10: NDC 58160-907-52 Store refrigerated between 2° and 8°C (36° and 46°F). Do not freeze. Discard if the vaccine has been frozen. Store in the original package to protect from light. Manufactured by: GlaxoSmithKline Biologicals , Dresden, Germany, a branch of SmithKline Beecham Pharma GmbH & Co. KG, Munich, Germany. Licensed by GlaxoSmithKline Biologicals , Rixensart, Belgium, U.S. License 1617. Distributed by GlaxoSmithKline, Research Triangle Park, NC 27709. Revised:  Jul 2017

OVERDOSE No information provided. CONTRAINDICATIONS Do not administer FLUARIX QUADRIVALENT to anyone with a history of severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or following a previous administration of any influenza vaccine [see DESCRIPTION].

SIDE EFFECTS The safety experience with FLUARIX (trivalent influenza vaccine) is relevant to FLUARIX QUADRIVALENT because both vaccines are manufactured using the same process and have overlapping compositions [see DESCRIPTION]. Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared with rates in the clinical trials of another vaccine, and may not reflect the rates observed in practice. There is the possibility that broad use of FLUARIX QUADRIVALENT could reveal adverse reactions not observed in clinical trials. In adults who received FLUARIX QUADRIVALENT, the most common (≥10%) injection site adverse reaction was pain (36%). The most common (≥10%) systemic adverse events were muscle aches (16%), headache (16%), and fatigue (16%). In children aged 3 through 17 years who received FLUARIX QUADRIVALENT, injection site adverse reactions were pain (44%), redness (23%), and swelling (19%). In children aged 3 through 5 years, the most common (≥10%) systemic adverse events were drowsiness (17%), irritability (17%), and loss of appetite (16%); in children aged 6 through 17 years, the most common systemic adverse events were fatigue (20%), muscle aches (18%), headache (16%), arthralgia (10%), and gastrointestinal symptoms (10%). FLUARIX QUADRIVALENT In Adults Trial 1 (NCT01204671) was a randomized, double-blind (2 arms) and open-label (one arm), activecontrolled, safety, and immunogenicity trial. In this trial, subjects received FLUARIX QUADRIVALENT (n = 3,036) or one of 2 formulations of comparator trivalent influenza vaccine (FLUARIX, TIV-1, n = 1,010 or TIV-2, n = 610), each containing an influenza type B virus that corresponded to one of the 2 type B viruses in FLUARIX QUADRIVALENT (a type B virus of the Victoria lineage or a type B virus of the Yamagata lineage). The population was aged 18 years and older (mean age: 58 years) and 57% were female; 69% were white, 27% were Asian, and 4% were of other racial/ethnic groups. Solicited events were collected for 7 days (day of vaccination and the next 6 days). The frequencies of solicited adverse events are shown in Table 2. Table 2: FLUARIX QUADRIVALENT: Incidence of Solicited Local Adverse Reactions and Systemic Adverse Events within 7 Daysa of Vaccination in Adultsb (Total Vaccinated Cohort) FLUARIX QUADRIVALENTc n = 3,011-3,015 % Trivalent Influenza Vaccine (TIV) TIV-1 (B Victoria)d n = 1,003 % TIV-2 (B Yamagata)e n = 607 % Any Grade 3f Any Grade 3f Any Grade 3f Local Pain 36.4 0.8 36.8 1.2 31.3 0.5 Redness 1.9 0.0 1.7 0.0 2.0 0.0 Swelling 2.1 0.0 2.1 0.0 1.3 0.0 Systemic Muscle aches 16.4 0.5 19.4 0.8 16.1 0.5 Headache 15.9 0.9 16.4 0.8 13.2 0.7 Fatigue 15.8 0.7 18.4 0.6 14.8 0.5 Arthralgia 8.4 0.5 10.4 0.7 9.4 0.3 Gastrointestinal symptomsg 6.5 0.4 6.5 0.2 5.9 0.3 Shivering 4.2 0.4 5.0 0.3 4.3 0.2 Feverh 1.6 0.0 1.2 0.0 1.5 0.0 Total vaccinated cohort for safety included all vaccinated subjects for whom safety data were available. n = number of subjects with diary card completed. aSeven days included day of vaccination and the subsequent 6 days. bTrial 1: NCT01204671. cContained the same composition as FLUARIX (trivalent formulation) manufactured for the 2010-2011 season and an additional influenza type B virus of Yamagata lineage. dContained the same composition as FLUARIX manufactured for the 2010-2011 season (2 influenza A subtype viruses and an influenza type B virus of Victoria lineage). eContained the same 2 influenza A subtype viruses as FLUARIX manufactured for the 2010-2011 season and an influenza type B virus of Yamagata lineage. fGrade 3 pain: Defined as significant pain at rest; prevented normal everyday activities. Grade 3 redness, swelling: Defined as >100 mm. Grade 3 muscle aches, headache, fatigue, arthralgia, gastrointestinal symptoms, shivering: Defined as prevented normal activity. Grade 3 fever: Defined as >102.2°F (39.0°C). gGastrointestinal symptoms included nausea, vomiting, diarrhea, and/or abdominal pain. hFever: Defined as ≥99.5°F (37.5°C). Unsolicited events occurring within 21 days of vaccination (Day 0 to 20) were reported in 13%, 14%, and 15% of subjects who received FLUARIX QUADRIVALENT, TIV-1, or TIV-2, respectively. The unsolicited adverse reactions that occurred most frequently (≥0.1% for FLUARIX QUADRIVALENT) included dizziness, injection site hematoma, injection site pruritus, and rash. Serious adverse events occurring within 21 days of vaccination were reported in 0.5%, 0.6%, and 0.2% of subjects who received FLUARIX QUADRIVALENT, TIV-1, or TIV-2, respectively. FLUARIX QUADRIVALENT In Children Trial 2 (NCT01196988) was a randomized, double-blind, active-controlled, safety, and immunogenicity trial. In this trial, subjects received FLUARIX QUADRIVALENT (n = 915) or one of 2 formulations of comparator trivalent influenza vaccine (FLUARIX, TIV-1, n = 912 or TIV-2, n = 911), each containing an influenza type B virus that corresponded to one of the 2 type B viruses in FLUARIX QUADRIVALENT (a type B virus of the Victoria lineage or a type B virus of the Yamagata lineage). Subjects were aged 3 through 17 years and 52% were male; 56% were white, 29% were Asian, 12% were black, and 3% were of other racial/ethnic groups. Children aged 3 through 8 years with no history of influenza vaccination received 2 doses approximately 28 days apart. Children aged 3 through 8 years with a history of influenza vaccination and children aged 9 years and older received one dose. Solicited local adverse reactions and systemic adverse events were collected using diary cards for 7 days (day of vaccination and the next 6 days). The frequencies of solicited adverse events are shown in Table 3. Table 3: FLUARIX QUADRIVALENT: Incidence of Solicited Local Adverse Reactions and Systemic Adverse Events within 7 Daysa after First Vaccination in Children Aged 3 through 17 Yearsb (Total Vaccinated Cohort) FLUARIX QUADRIVALENTc % Trivalent Influenza Vaccine (TIV) TIV-1 (B Victoria)d % TIV-2 (B Yamagata)e % Any Grade 3f Any Grade 3f Any Grade 3f Aged 3 through 17 Years Local n = 903 n = 901 n = 905 Paing 43.7 1.6 42.4 1.8 40.3 0.8 Redness 23.0 1.0 21.3 0.2 20.9 0.7 Swelling 18.5 0.8 17.2 1.1 14.9 0.2 Aged 3 through 5 Years Systemic n = 291 n = 314 n = 279 Drowsiness 17.2 1.0 12.4 0.3 13.6 0.7 Irritability 16.8 0.7 13.4 0.3 14.3 0.7 Loss of appetite 15.5 0.3 8.0 0.0 10.4 0.7 Feverh 8.9 0.3 8.9 0.3 8.2 1.1 Aged 6 through 17 Years Systemic n = 613 n = 588 n = 626 Fatigue 19.7 1.5 18.5 1.4 15.5 0.5 Muscle aches 17.5 0.7 16.0 1.4 15.8 0.5 Headache 16.3 1.3 19.2 0.7 15.2 0.6 Arthralgia 9.8 0.3 9.4 0.7 7.3 0.2 Gastrointestinal symptomsi 9.8 1.0 9.5 0.7 7.2 0.3 Shivering 6.4 0.5 4.4 0.5 5.0 0.0 Feverh 6.0 1.1 8.5 0.5 6.1 0.3 Total vaccinated cohort for safety included all vaccinated subjects for whom safety data were available.  n = number of subjects with diary card completed. aSeven days included day of vaccination and the subsequent 6 days. bTrial 2: NCT01196988. cContained the same composition as FLUARIX (trivalent formulation) manufactured for the 2010-2011 season and an additional influenza type B virus of Yamagata lineage. dContained the same composition as FLUARIX manufactured for the 2010-2011 season (2 influenza A subtype viruses and an influenza type B virus of Victoria lineage). eContained the same 2 influenza A subtype viruses as FLUARIX manufactured for the 2010-2011 season and an influenza type B virus of Yamagata lineage. fGrade 3 pain: Defined as cried when limb was moved/spontaneously painful (children 6 years), or significant pain at rest, prevented normal everyday activities (children ≥6 years). Grade 3 redness, swelling: Defined as >50 mm. Grade 3 drowsiness: Defined as prevented normal activity. Grade 3 irritability: Defined as crying that could not be comforted/prevented normal activity. Grade 3 loss of appetite: Defined as not eating at all. Grade 3 fever: Defined as >102.2°F (39.0°C). Grade 3 fatigue, muscle aches, headache, arthralgia, gastrointestinal symptoms, shivering: Defined as prevented normal activity. gPercentage of subjects with any pain by age subgroup: 39%, 38%, and 37% for FLUARIX QUADRIVALENT, TIV-1, and TIV-2, respectively, in children aged 3 through 8 years and 52%, 50%, and 46% for FLUARIX QUADRIVALENT, TIV-1, and TIV-2, respectively, in children aged 9 through 17 years. hFever: Defined as ≥99.5°F (37.5°C). iGastrointestinal symptoms included nausea, vomiting, diarrhea, and/or abdominal pain. In children who received a second dose of FLUARIX QUADRIVALENT, TIV-1, or TIV-2, the incidences of adverse events following the second dose were generally lower than those observed after the first dose. Unsolicited adverse events occurring within 28 days of any vaccination were reported in 31%, 33%, and 34% of subjects who received FLUARIX QUADRIVALENT, TIV-1, or TIV-2, respectively. The unsolicited adverse reactions that occurred most frequently (≥0.1% for FLUARIX QUADRIVALENT) included injection site pruritus and rash. Serious adverse events occurring within 28 days of any vaccination were reported in 0.1%, 0.1%, and 0.1% of subjects who received FLUARIX QUADRIVALENT, TIV-1, or TIV-2, respectively. FLUARIX (Trivalent Formulation) FLUARIX has been administered to 10,317 adults aged 18 through 64 years, 606 subjects aged 65 years and older, and 2,115 children aged 6 months through 17 years in clinical trials. The incidence of solicited adverse events in each age-group is shown in Tables 4 and 5. Table 4: FLUARIX (Trivalent Formulation): Incidence of Solicited Local Adverse Reactions and Systemic Adverse Events within 4 Daysa of Vaccination in Adults (Total Vaccinated Cohort) Trial 3b Trial 4c Aged 18 through 64 Years Aged 65 Years and Older FLUARIX n = 760 % Placebo n = 192 % FLUARIX n = 601-602 % Comparator n = 596 % Any Gr 3d Any Gr 3d Any Gr 3d Any Gr 3d Local Pain 54.7 0.1 12.0 0.0 19.1 0.0 17.6 0.0 Redness 17.5 0.0 10.4 0.0 10.6 0.2 13.1 0.7 Swelling 9.3 0.1 5.7 0.0 6.0 0.0 8.9 0.7 Systemic Muscle aches 23.0 0.4 12.0 0.5 7.0 0.3 6.5 0.0 Fatigue 19.7 0.4 17.7 1.0 9.0 0.3 9.6 0.7 Headache 19.3 0.1 21.4 1.0 7.5 0.3 7.9 0.3 Arthralgia 6.4 0.1 6.3 0.5 5.5 0.5 5.0 0.2 Shivering 3.3 0.1 2.6 0.0 1.7 0.2 2.2 0.0 Fevere 1.7 0.0 1.6 0.0 1.7 0.0 0.5 0.0 Total vaccinated cohort for safety included all vaccinated subjects for whom safety data were available. n = number of subjects with diary card completed. Gr 3 = Grade 3. aFour days included day of vaccination and the subsequent 3 days. bTrial 3 was a randomized, double-blind, placebo-controlled, safety, and immunogenicity trial (NCT00100399). cTrial 4 was a randomized, single-blind, active-controlled, safety, and immunogenicity trial (NCT00197288). The active control was FLUZONE , a U.S.-licensed trivalent, inactivated influenza vaccine (Sanofi Pasteur Inc.). dGrade 3 pain, muscle aches, fatigue, headache, arthralgia, shivering: Defined as prevented normal activity. Grade 3 redness, swelling: Defined as >50 mm. Grade 3 fever: Defined as >102.2°F (39.0°C). eFever: Defined as ≥100.4°F (38.0°C) in Trial 3, and ≥99.5°F (37.5°C) in Trial 4. Table 5: FLUARIX (Trivalent Formulation): Incidence of Solicited Local Adverse Reactions and Systemic Adverse Events within 4 Daysa of First Vaccination in Children Aged 3 through 17 Yearsb (Total Vaccinated Cohort) Aged 3 through 4 Years Aged 5 through 17 Years FLUARIX n = 350 % Comparator n = 341 % FLUARIX n = 1,348 % Comparator n = 451 % Any Gr 3c Any Gr 3c Any Gr 3c Any Gr 3c Local Pain 34.9 1.7 38.4 1.2 56.2 0.8 56.1 0.7 Redness 22.6 0.3 19.9 0.0 17.7 1.0 16.4 0.7 Swelling 13.7 0.0 13.2 0.0 13.9 1.5 13.3 0.7 Systemic Irritability 20.9 0.9 22.0 0.0 Loss of appetite 13.4 0.9 15.0 0.9 — — — — Drowsiness 13.1 0.6 19.6 0.9 — — — — Feverd 6.6 1.4 7.6 1.5 4.2 0.3 3.3 0.2 Muscle aches — — — — 28.8 0.4 28.8 0.4 Fatigue — — — — 19.9 1.0 18.8 1.1 Headache — — — — 15.1 0.5 16.4 0.9 Arthralgia — — — — 5.6 0.1 6.2 0.2 Shivering — — — — 3.1 0.1 3.5 0.2 Total vaccinated cohort for safety included all vaccinated subjects for whom safety data were available. n = number of subjects with diary card completed. Gr 3 = Grade 3. aFour days included day of vaccination and the subsequent 3 days. bTrial 6 was a single-blind, active-controlled, safety, and immunogenicity U.S. trial (NCT00383123). The active control was FLUZONE, a U.S.-licensed trivalent, inactivated influenza vaccine (Sanofi Pasteur Inc.). cGrade 3 pain, irritability, loss of appetite, drowsiness, muscle aches, fatigue, headache, arthralgia, shivering: Defined as prevented normal activity. Grade 3 swelling, redness: Defined as >50 mm. Grade 3 fever: Defined as >102.2°F (39.0°C). dFever: Defined as ≥99.5°F (37.5°C). In children who received a second dose of FLUARIX or the comparator vaccine, the incidences of adverse events following the second dose were similar to those observed after the first dose. Serious Adverse Events In the 4 clinical trials in adults (N = 10,923), there was a single case of anaphylaxis within one day following administration of FLUARIX (<0.01%). Postmarketing Experience Beyond those events reported above in the clinical trials for FLUARIX QUADRIVALENT or FLUARIX, the following adverse events have been spontaneously reported during postapproval use of FLUARIX (trivalent influenza vaccine). This list includes serious events or events which have causal connection to FLUARIX. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to the vaccine. Blood And Lymphatic System Disorders Lymphadenopathy. Cardiac Disorders Tachycardia. Ear And Labyrinth Disorders Vertigo. Eye Disorders Conjunctivitis, eye irritation, eye pain, eye redness, eye swelling, eyelid swelling. Gastrointestinal Disorders Abdominal pain or discomfort, swelling of the mouth, throat, and/or tongue. General Disorders And Administration Site Conditions Asthenia, chest pain, feeling hot, injection site mass, injection site reaction, injection site warmth, body aches. Immune System Disorders Anaphylactic reaction including shock, anaphylactoid reaction, hypersensitivity, serum sickness. Infections And Infestations Injection site abscess, injection site cellulitis, pharyngitis, rhinitis, tonsillitis. Nervous System Disorders Convulsion, encephalomyelitis, facial palsy, facial paresis, Guillain-Barré syndrome, hypoesthesia, myelitis, neuritis, neuropathy, paresthesia, syncope. Respiratory, Thoracic, And Mediastinal Disorders Asthma, bronchospasm, dyspnea, respiratory distress, stridor. Skin And Subcutaneous Tissue Disorders Angioedema, erythema, erythema multiforme, facial swelling, pruritus, Stevens-Johnson syndrome, sweating, urticaria. Vascular Disorders Henoch-Schönlein purpura, vasculitis. DRUG INTERACTIONS Concomitant Vaccine Administration FLUARIX QUADRIVALENT should not be mixed with any other vaccine in the same syringe or vial. There are insufficient data to assess the concurrent administration of FLUARIX QUADRIVALENT with other vaccines. When concomitant administration of other vaccines is required, the vaccines should be administered at different injection sites. Immunosuppressive Therapies Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater-than-physiologic doses), may reduce the immune response to FLUARIX QUADRIVALENT.

WARNINGS Included as part of the PRECAUTIONS section. PRECAUTIONS Guillain-Barré Syndrome If GuillainBarré syndrome (GBS) has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUARIX QUADRIVALENT should be based on careful consideration of the potential benefits and risks. The 1976 swine influenza vaccine was associated with an increased frequency of GBS. Evidence for a causal relation of GBS with subsequent vaccines prepared from other influenza viruses is inconclusive. If influenza vaccine does pose a risk, it is probably slightly more than one additional case/one million persons vaccinated. Syncope Syncope (fainting) can occur in association with administration of injectable vaccines, including FLUARIX QUADRIVALENT. Syncope can be accompanied by transient neurological signs such as visual disturbance, paresthesia, and tonic-clonic limb movements. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope. Preventing And Managing Allergic Vaccine Reactions Prior to administration, the healthcare provider should review the immunization history for possible vaccine sensitivity and previous vaccinationrelated adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of FLUARIX QUADRIVALENT. Altered Immunocompetence If FLUARIX QUADRIVALENT is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons. Limitations Of Vaccine Effectiveness Vaccination with FLUARIX QUADRIVALENT may not protect all susceptible individuals. Persons At Risk Of Bleeding As with other intramuscular injections, FLUARIX QUADRIVALENT should be given with caution in individuals with bleeding disorders, such as hemophilia or on anticoagulant therapy, to avoid the risk of hematoma following the injection. Nonclinical Toxicology Carcinogenesis, Mutagenesis, Impairment Of Fertility FLUARIX QUADRIVALENT has not been evaluated for carcinogenic or mutagenic potential or male infertility in animals. Vaccination of female rats with FLUARIX QUADRIVALENT had no effect on fertility [see Use In Specific Populations]. Use In Specific Populations Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to FLUARIX QUADRIVALENT during pregnancy. Healthcare providers are encouraged to register women by calling 1-888-452-9622. Risk Summary All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. There are insufficient data on FLUARIX QUADRIVALENT in pregnant women to inform vaccineassociated risks. A developmental toxicity study was performed in female rats administered FLUARIX QUADRIVALENT prior to mating and during gestation and lactation periods. The total dose was 0.2 mL at each occasion (a single human dose is 0.5 mL). This study revealed no adverse effects on fetal or pre-weaning development due to FLUARIX QUADRIVALENT [see Data]. Clinical Considerations Disease-Associated Maternal And/Or Embryo/Fetal Risk Pregnant women infected with seasonal influenza are at increased risk of severe illness associated with influenza infection compared with non-pregnant women. Pregnant women with influenza may be at increased risk for adverse pregnancy outcomes, including preterm labor and delivery. Data Animal Data In a developmental toxicity study, female rats were administered FLUARIX QUADRIVALENT by intramuscular injection 4 and 2 weeks prior to mating, on gestation Days 3, 8, 11, and 15, and on lactation Day 7. The total dose was 0.2 mL at each occasion (a single human dose is 0.5 mL). No adverse effects on pre-weaning development up to post-natal Day 25 were observed. There were no vaccine-related fetal malformations or variations. Lactation Risk Summary It is not known whether FLUARIX QUADRIVALENT is excreted in human milk. Data are not available to assess the effects of FLUARIX QUADRIVALENT on the breastfed infant or on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for FLUARIX QUADRIVALENT and any potential adverse effects on the breastfed child from FLUARIX QUADRIVALENT or from the underlying maternal condition. For preventive vaccines, the underlying maternal condition is susceptibility to disease prevented by the vaccine. Pediatric Use Safety and effectiveness of FLUARIX QUADRIVALENT in children younger than 3 years have not been established. Safety and immunogenicity of FLUARIX QUADRIVALENT in children aged 3 through 17 years have been evaluated [see ADVERSE REACTIONS, Clinical Studies]. Geriatric Use In a randomized, double-blind (2 arms) and open-label (one arm), active-controlled trial, immunogenicity and safety were evaluated in a cohort of subjects aged 65 years and older who received FLUARIX QUADRIVALENT (n = 1,517); 469 of these subjects were aged 75 years and older. In subjects aged 65 years and older, the geometric mean antibody titers (GMTs) post-vaccination and seroconversion rates were lower than in younger subjects (aged 18 through 64 years) and the frequencies of solicited and unsolicited adverse events were generally lower than in younger subjects.